Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Oppenheimer Maintains Outperform on Artivion, Lowers Price Target to $25

Oppenheimer Maintains Outperform on Artivion, Lowers Price Target to $25

Oppenheimer analyst Suraj Kalia maintains Artivion (NYSE:AORT) with a Outperform and lowers the price target from $35 to $25.

byBenzinga Newsdesk

September 26, 2022

1 minute read

Oppenheimer analyst Suraj Kalia maintains Artivion (NYSE:AORT) with a Outperform and lowers the price target from $35 to $25.

Citigroup Maintains Neutral on Celestica, Raises Price Target to $12

By Benzinga Newsdesk

October 26, 10:37 AM

Citigroup analyst Jim Suva maintains Celestica (NYSE:CLS) with a Neutral and raises the price target from $10 to $12.

CLS

Biden, Under Fire Over ‘No Comment’ Remark On Rising Hawaii Death Toll, Says Will Visit Maui ‘As Soon As We Can’

By Benzinga Neuro

August 15, 8:47 PM

President Joe Biden has come under criticism for his handling of the devastating wildfires in Maui, which have…

BOH

Is Apple Losing Its Spark? Recent Sales Figures Suggest So.

By Bibhu Pattnaik

September 17, 12:43 PM

While the market is upbeat about the new iPhone 15 from Apple Inc. (NASDAQ:

AAPL

Stride Company MedCerts Appoints Craig Sprinkle As CEO

By Shivani Kumaresan

November 28, 11:26 AM

Stride Inc (NYSE:LRN) owned eLearning solutions provider, MedCerts has appointed Craig Sprinkle as Chief Executive Officer. Sprinkle will succeed CEO…

LRN

Oppenheimer Maintains Outperform on Artivion, Lowers Price Target to $25

Related Posts

Citigroup Maintains Neutral on Celestica, Raises Price Target to $12

Biden, Under Fire Over ‘No Comment’ Remark On Rising Hawaii Death Toll, Says Will Visit Maui ‘As Soon As We Can’

Is Apple Losing Its Spark? Recent Sales Figures Suggest So.

Stride Company MedCerts Appoints Craig Sprinkle As CEO